Answers are grounded in this paper and cite their sources.
INTRODUCTION: Gynaecological cancers increasingly affect women of reproductive age, necessitating fertility-sparing treatments that balance oncological safety with reproductive potential. However, the long-term impact of these treatments on survivorship-specifically regarding sexual function, quality of life (QoL) and reproductive outcomes-remains understudied. LIFE-Repro is a prospective multicentre cohort study designed to evaluate these impacts in young female cancer survivors. METHODS AND ANALYSIS: Between 2023 and 2027, eleven tertiary referral hospitals in Korea will recruit 200 patients aged ≤45 years with gynaecological cancers who have undergone fertility-sparing treatment. Participants will undergo baseline assessments followed by prospective follow-ups every 6 months. At each visit, patient-reported outcomes assessing sexual function, QoL and health status will be collected using a mobile application developed by the research team. The primary endpoint is the incidence of post-treatment sexual dysfunction measured by the Female Sexual Function Index-Korean version. Secondary endpoints include longitudinal changes in QoL, cancer recurrence, survival, pregnancy rates, live birth rates and premature menopause. ETHICS AND DISSEMINATION: The study protocol was approved by the Institutional Review Board of Korea University Guro Hospital (2024GR0484). Results will be disseminated through peer-reviewed journals and conference presentations. TRIAL REGISTRATION NUMBER: KCT0009578.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: